LivaNova PLC (NASDAQ:LIVN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

LivaNova PLC (NASDAQ:LIVN) has been assigned a consensus rating of “Moderate Buy” from the eleven analysts that are covering the stock, MarketBeat reports. Five equities research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $84.1250.

LIVN has been the subject of a number of research analyst reports. Zacks Research downgraded LivaNova from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Freedom Capital raised shares of LivaNova to a “hold” rating in a report on Tuesday, June 30th. Mizuho upped their price objective on LivaNova from $90.00 to $95.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Stifel Nicolaus set a $85.00 price objective on LivaNova in a research note on Wednesday, August 5th. Finally, KeyCorp lifted their target price on shares of LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Monday, June 22nd.

Insider Buying and Selling

In other news, Director Francesco Bianchi sold 3,500 shares of LivaNova stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $78.01, for a total transaction of $273,035.00. Following the completion of the sale, the director owned 4,434 shares in the company, valued at approximately $345,896.34. This trade represents a 44.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Brooke Story sold 2,300 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $81.42, for a total value of $187,266.00. Following the transaction, the director directly owned 7,488 shares of the company’s stock, valued at $609,672.96. The trade was a 23.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 7,450 shares of company stock worth $591,839 in the last ninety days. 0.35% of the stock is currently owned by insiders.

Institutional Trading of LivaNova

Several hedge funds and other institutional investors have recently bought and sold shares of LIVN. Millennium Management LLC boosted its holdings in LivaNova by 17.3% during the 4th quarter. Millennium Management LLC now owns 3,484,082 shares of the company’s stock valued at $214,376,000 after acquiring an additional 514,268 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of LivaNova by 2.1% during the first quarter. Dimensional Fund Advisors LP now owns 1,826,248 shares of the company’s stock valued at $116,067,000 after acquiring an additional 38,320 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of LivaNova by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 1,458,838 shares of the company’s stock worth $89,775,000 after purchasing an additional 12,750 shares during the period. LSV Asset Management boosted its holdings in shares of LivaNova by 2.7% during the fourth quarter. LSV Asset Management now owns 693,110 shares of the company’s stock worth $42,647,000 after purchasing an additional 18,500 shares during the period. Finally, Janus Henderson Group PLC grew its stake in shares of LivaNova by 1,978.8% in the first quarter. Janus Henderson Group PLC now owns 471,379 shares of the company’s stock worth $29,961,000 after purchasing an additional 448,703 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Price Performance

LIVN opened at $78.01 on Monday. LivaNova has a 1 year low of $48.82 and a 1 year high of $85.76. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.45 and a quick ratio of 1.21. The company has a market capitalization of $4.30 billion, a price-to-earnings ratio of 23.08 and a beta of 0.87. The firm’s fifty day moving average price is $79.93 and its two-hundred day moving average price is $73.64.

LivaNova (NASDAQ:LIVN) last announced its earnings results on Thursday, August 6th. The company reported $1.26 EPS for the quarter, beating the consensus estimate of $1.09 by $0.17. LivaNova had a net margin of 12.82% and a return on equity of 16.35%. The company had revenue of $390.59 million during the quarter, compared to the consensus estimate of $380.50 million. During the same quarter in the prior year, the company posted $1.05 earnings per share. The firm’s revenue for the quarter was up 10.8% on a year-over-year basis. As a group, analysts anticipate that LivaNova will post 3.77 earnings per share for the current fiscal year.

LivaNova Company Profile

LivaNova PLC (NASDAQ: LIVN) is a medical device company that develops and manufactures technologies for the treatment of neurological and cardiovascular conditions. The company serves hospitals, physicians and patients in markets around the world, with operations and commercial activities spanning North America, Europe and other international markets.

LivaNova’s Neuromodulation business produces vagus nerve stimulation (VNS) systems marketed under the VNS Therapy brand. These implantable devices are used as an adjunctive treatment for drug-resistant epilepsy and are designed to deliver programmed electrical stimulation to the vagus nerve.